141 related articles for article (PubMed ID: 38402087)
1. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
[TBL] [Abstract][Full Text] [Related]
2. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
3. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive prediction of IDH mutation status in gliomas using preoperative multiparametric MRI radiomics nomogram: A mutlicenter study.
Lu J; Xu W; Chen X; Wang T; Li H
Magn Reson Imaging; 2023 Dec; 104():72-79. PubMed ID: 37778708
[TBL] [Abstract][Full Text] [Related]
5. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
[TBL] [Abstract][Full Text] [Related]
6. Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
Park YW; Kim S; Park CJ; Ahn SS; Han K; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2022 Dec; 32(12):8089-8098. PubMed ID: 35763095
[TBL] [Abstract][Full Text] [Related]
7. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas.
Jiang C; Kong Z; Zhang Y; Liu S; Liu Z; Chen W; Liu P; Liu D; Wang Y; Lyu Y; Zhao D; Wang Y; You H; Feng F; Ma W
Neuroradiology; 2020 Jul; 62(7):803-813. PubMed ID: 32239241
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Prediction of TERT Promoter Mutations in High-Grade Glioma by Radiomics Analysis Based on Multiparameter MRI.
Tian H; Wu H; Wu G; Xu G
Biomed Res Int; 2020; 2020():3872314. PubMed ID: 32509858
[TBL] [Abstract][Full Text] [Related]
9. Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas.
Arita H; Kinoshita M; Kawaguchi A; Takahashi M; Narita Y; Terakawa Y; Tsuyuguchi N; Okita Y; Nonaka M; Moriuchi S; Takagaki M; Fujimoto Y; Fukai J; Izumoto S; Ishibashi K; Nakajima Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Mori K; Ichimura K; Kanemura Y
Sci Rep; 2018 Aug; 8(1):11773. PubMed ID: 30082856
[TBL] [Abstract][Full Text] [Related]
10. Radiomic study on preoperative multi-modal magnetic resonance images identifies IDH-mutant TERT promoter-mutant gliomas.
Wang H; Zhang S; Xing X; Yue Q; Feng W; Chen S; Zhang J; Xie D; Chen N; Liu Y
Cancer Med; 2023 Feb; 12(3):2524-2537. PubMed ID: 36176070
[TBL] [Abstract][Full Text] [Related]
11. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
[TBL] [Abstract][Full Text] [Related]
12. A radiomics feature-based nomogram to predict telomerase reverse transcriptase promoter mutation status and the prognosis of lower-grade gliomas.
Lu J; Li X; Li H
Clin Radiol; 2022 Aug; 77(8):e560-e567. PubMed ID: 35595562
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
14. A radiomics-based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma.
Li Y; Chen L; Huang L; Li X; Huang Q; Tang L; Huang Z; Zhu L; Li T
Brain Behav; 2024 May; 14(5):e3528. PubMed ID: 38798094
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
[TBL] [Abstract][Full Text] [Related]
16. Impact of signal intensity normalization of MRI on the generalizability of radiomic-based prediction of molecular glioma subtypes.
Foltyn-Dumitru M; Schell M; Rastogi A; Sahm F; Kessler T; Wick W; Bendszus M; Brugnara G; Vollmuth P
Eur Radiol; 2024 Apr; 34(4):2782-2790. PubMed ID: 37672053
[TBL] [Abstract][Full Text] [Related]
17. A radiomics model based on DCE-MRI and DWI may improve the prediction of estimating IDH1 mutation and angiogenesis in gliomas.
Wang J; Hu Y; Zhou X; Bao S; Chen Y; Ge M; Jia Z
Eur J Radiol; 2022 Feb; 147():110141. PubMed ID: 34995947
[TBL] [Abstract][Full Text] [Related]
18. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813
[TBL] [Abstract][Full Text] [Related]
19. Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach.
Cao M; Suo S; Zhang X; Wang X; Xu J; Yang W; Zhou Y
Biomed Res Int; 2021; 2021():1235314. PubMed ID: 33553421
[TBL] [Abstract][Full Text] [Related]
20. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
